ERBB agonist-1

• Description :

  ERBB agonist-1 (Compound EF-1) is an agonist for ERBB4, that activates the ERBB4 signaling pathway by inducing dimerization of the ERBB4 receptor with an EC50 of 10.5 μM. ERBB agonist-1 induces phosphorylation of Akt and ERK1/2, reduces the collagen expression in cardiac fibroblasts, inhibits H2O2-induced cardiomyocyte death and Ang II (HY-13948) -induced cardiomyocyte hypertrophy. ERBB agonist-1 prevents fibrosis and exhibits cardioprotective efficacy in mouse models[1].

• UNSPSC :

  12352005

• Target :

  Akt; EGFR; ERK

• Related Pathways :

  JAK/STAT Signaling; MAPK/ERK Pathway; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

• Applications :

  Neuroscience-Neuromodulation

• Field of Research :

  Cardiovascular Disease

• Purity :

  99.16

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  O=C(NC1CC1)C(SC(N2C3CCCC3)=NC4=CC=CC=C4C2=O)C5=CC=CC=C5

• Molecular Formula :

  C24H25N3O2S

• Molecular Weight :

  419.54

• References & Citations :

  [1]Cools JMT, et al., Small-molecule-induced ERBB4 activation to treat heart failure. Nat Commun. 2025 Jan 10;16 (1) :576.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [930856-19-2]